Efficiacy And Freedom From Side Effects of Slow-Release Ferrous Sulphate (‘‘Feospan Spansules’’)

1963 ◽  
Vol 49 (2) ◽  
pp. 121-123
Author(s):  
M. L. J. Segall ◽  
L. P. Sayers ◽  
L. R. Sweetman ◽  
R. C. Tyner
Keyword(s):  
Side Effects ◽  
Slow Release ◽  
Ferrous Sulphate

scholarly journals Mesalazine (5-aminosalicylic acid) induced chronic hepatitis

Gut ◽  
1999 ◽  
Vol 44 (6) ◽  
pp. 886-888 ◽  
Author(s):  
P Deltenre ◽  
A Berson ◽  
P Marcellin ◽  
C Degott ◽  
M Biour ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Side Effects ◽  
Adverse Effects ◽  
Liver Dysfunction ◽  
Liver Enzymes ◽  
Slow Release ◽  
Aminosalicylic Acid ◽  
Safe Alternative ◽  
Release Formulation ◽  
Slow Release Formulation

BACKGROUNDTreatment of ulcerative colitis or Crohn’s disease with sulphasalazine causes several adverse effects, including hepatitis. Sulphasalazine is cleaved by colonic bacteria into 5-aminosalicylic acid and sulphapyridine. Received wisdom was that 5-aminosalicylic acid was topically active, whereas sulphapyridine was absorbed and caused immunoallergic side effects. Mesalazine, a slow release formulation of 5-aminosalicylic acid, was expected to be a safe alternative. However, several cases of acute hepatitis have been reported.CASE REPORTA 65 year old man had increased liver enzymes, anti-nuclear and anti-smooth muscle autoantibodies and IgG levels, and lesions of chronic hepatitis after 21 months of mesalazine treatment. Although liver dysfunction had been identified eight months earlier, simvastatin rather than mesalazine had been withdrawn, without any improvement. In contrast, liver enzyme and IgG levels became normal and autoantibodies disappeared after discontinuation of mesalazine administration.CONCLUSIONContrary to initial expectations, mesalazine can cause most of the sulphasalazine induced adverse effects, and hepatic side effects may be almost as frequent. When liver dysfunction occurs, mesalazine administration should be discontinued to avoid the development of chronic hepatitis and liver fibrosis.

Iron and folic acid in pregnancy: ferrograd folic

1968 ◽  
Vol 6 (3) ◽  
pp. 12.1-12
Keyword(s):  
Folic Acid ◽  
Iron Deficiency ◽  
Slow Release ◽  
Ferrous Sulphate ◽  
Elemental Iron ◽  
Ferrous Fumarate ◽  
Iron And Folic Acid ◽  
In Pregnancy

Abbott Laboratories have drawn our attention to their Ferrograd Folic tablets which were introduced shortly after we discussed combined iron and folic acid tablets (DTB March 17, 1967, p. 22.). Like A. H. Cox’s ferrous fumarate and folic acid tablet (DTB November 24, 1967, p. 96), Ferrograd Folic provides what we concluded were appropriate amounts of folic acid and iron for prophylaxis of folate and iron deficiency in pregnancy. Each tablet contains 350 mcg folic acid and 105 mg elemental iron as slowly released ferrous sulphate; the dose is one tablet daily. The basic NHS cost of one week’s supply is 1/9d, much more than that of Cox’s tablets, but slow release of the iron is probably an advantage for some patients.

Once-Daily Treatment for Mixed Anxiety/Depressive States: A Comparison of Slow Release Amitriptyline and Fluphenazine with Nortriptyline

1977 ◽  
Vol 5 (2) ◽  
pp. 109-113 ◽  
Author(s):  
R V Magnus ◽  
A A Schiff
Keyword(s):  
Side Effects ◽  
Sustained Release ◽  
Slow Release ◽  
Anxiolytic Effect ◽  
Daily Treatment ◽  
Dry Mouth ◽  
Double Blind ◽  
Once Daily ◽  
Therapeutic Advantage ◽  
Depressive States

Patients suffering from mixed anxiety/depressive states referred to a psychiatric out-patient clinic completed a four week course of either a once-daily tablet of 30 mg nortriptyline with 1· 5 mg fluphenazine, or a sustained release capsule of 50 mg amitriptyline once daily, on a double-blind basis. Depression improved satisfactorily on either treatment, but there was a greater reduction of anxiety on fluphenazine/nortriptyline. Drowsiness, however, occurred more frequently among the patients on amitriptyline, suggesting the sedative properties of this drug did not substitute adequately for a specific anxiolytic effect. Dry mouth was also noticeably more frequent with amitriptyline. As might be expected on pharmacokinetic and physiological grounds, the results suggest that the sustained release characteristics of the amitriptyline preparation lead to a maximization of side-effects during the day without conferring any therapeutic advantage.

Can Iron and Folic Acid-IFA and Ca & Vitamin D Supplementation in Pregnancy be Fitted into Habitual Pattern of Three Meals A Day?

2019 ◽  
Vol 56 (4) ◽  
pp. 341
Author(s):  
Prema Ramachandran ◽  
Amrita Pramanik ◽  
K. Kalaivani
Keyword(s):  
Vitamin D ◽  
Folic Acid ◽  
Side Effects ◽  
Pregnant Women ◽  
Ferrous Sulphate ◽  
Vitamin D Supplementation ◽  
Meal Pattern ◽  
Iron And Folic Acid ◽  
Habitual Pattern ◽  
In Pregnancy

In India prevalence of anaemia and vitamin D deficiency in pregnancy are widespread. National programmes recommend that two tablets of iron and folic acid (IFA) and two tablets of calcium and vitamin D (Ca & Vit D) to be given every day from second trimester till delivery. To minimize the side effects and increase compliance, it is advised that each tablet should be taken after a meal. Most households follow a three meal pattern. A study was taken up to find out how IFA and Ca & Vit D supplementations can be fitted into the habitual three meal pattern. A short term crossover supplementation study was carried out on 38 pregnant women to assess side effects following consumption after lunch of one or two tablets containing 500mg elemental calcium (as calcium carbonate) and 250 IU vitamin D or 60 mg of elemental iron as ferrous sulphate. Prevalence of side effects was higher in women who received iron supplements as compared to Ca & Vit D supplements. Taking two tablets of Ca & Vit D together after meal was associated with significantly higher prevalence of side effects as compared to taking one tablet after meal. Taking two tablets of iron together after meal was not associated with any significant increase in prevalence of side effects as compared to one tablet. Giving two tablets of iron together after one meal and giving one tablet of calcium and vitamin after two meals is feasible option for providing two tablets each of iron and Ca & Vit D to pregnant women who habitually follow a three meal pattern.

No Effect Of Persantin On Platelet Aggregation And Plasma βTg Levels In Healthy Volunteers

1981 ◽  
Author(s):  
A W A Lensing ◽  
A Sturk ◽  
J W ten Cate
Keyword(s):  
Side Effects ◽  
Healthy Volunteers ◽  
Cerebrovascular Accident ◽  
Slow Release ◽  
Double Blind Study ◽  
Prolonged Administration ◽  
Double Blind ◽  
Normal Limits ◽  
Induced Aggregation ◽  
Release Form

Previous studies from our laboratory revealed no effect of aspirin on plasma βTG levels in healthy volunteers as well as in patients with cerebrovascular accident. This double blind study was undertaken to investigate the effect of prolonged administration of Persantin. Two groups of 10 volunteers each received 4×100 mg Persantin or 2×200 mg daily in slow release form for 21 days. Platelet studies were performed prior to- and once every week during the trial. The volunteers refrained from smoking and were not on oral contraceptives or other drugs. No effect was observed on ADP (1 μ M f.c.) or collagen induced aggregation. All βTG plasma levels were within normal limits i.e. below 60/ml of plasma. No tendency of decreasing levels was observed. Side effects were significantly more observed in the volunteers on slow release Persantin (Mean Whitney Test α < 0.025). Side effects included sensations of a dry mouth and thirst, headache and di2Lzyness.

Patient Preference for Slow Release Potassium Supplements

1975 ◽  
Vol 3 (2) ◽  
pp. 101-103 ◽  
Author(s):  
D M Fraser ◽  
D N S Malone
Keyword(s):  
Side Effects ◽  
Patient Preference ◽  
Slow Release

A comparative, cross-over trial was conducted to determine patient preference for the slow release potassium supplements Slow K and Leo K. Fifty-seven patients took part in the trial and the majority found Leo K preferable to Slow K, principally because Leo K was easier to swallow and caused fewer side-effects. In order to increase the chances of patients following the prescriber's instructions it would seem logical to prescribe Leo K rather than Slow K on the basis of patient preference.

Slow-Release Terbutaline and Theophylline for the Long-Term Therapy of Children With Asthma: A Latin Square and Factorial Study of Drug Effects and Interactions

PEDIATRICS ◽  
1989 ◽  
Vol 84 (1) ◽  
pp. 119-125
Author(s):  
Olivia Kit Wun Chow ◽  
Kam Pui Fung
Keyword(s):  
Side Effects ◽  
Slow Release ◽  
Clinical Symptoms ◽  
Combined Therapy ◽  
Latin Square ◽  
Term Therapy ◽  
Long Term Effects ◽  
Long Term Treatment ◽  
Children With Asthma

To evaluate the long-term effects of slow-release formulations of theophylline and terbutaline on pulmonary function, clinical symptoms, and side effects, 24 children with stable and moderately severe perennial asthma participated in a prospective double-blind crossover study. The patients and the treatments were randomized according to the Latin square design to eliminate all possible period/climate biases throughout the protracted study period. The treatments consisted of terbutaline, 5 mg, theophylline, 200 mg, the combination, and placebo, given twice daily orally and crossing over every 28 days. The two drugs, administered alone or in combination, improved lung function and symptoms when compared with placebo. The interaction of theophylline and terbutaline was quantitatively shown by 2 x 2 factorial statistical design to be essentially additive rather than synergistic in the control of asthma. No increase in side effects was noted when the combined therapy was used. These findings suggest therapeutic advantages to combining submaximal oral doses of sustained-release theophylline and terbutaline for the long-term treatment of children with asthma.

scholarly journals Evaluation of the Treatment of Thyrotropin-Secreting Pituitary Adenomas with a Slow Release Formulation of the Somatostatin Analog Lanreotide

2000 ◽  
Vol 85 (4) ◽  
pp. 1487-1491 ◽  
Author(s):  
J. M. Kuhn ◽  
S. Arlot ◽  
H. Lefebvre ◽  
P. Caron ◽  
C. Cortet-Rudelli ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Side Effects ◽  
Pituitary Adenomas ◽  
Slow Release ◽  
Somatostatin Analogs ◽  
Clinical Signs ◽  
Resonance Imaging ◽  
Release Formulation ◽  
Α Subunit ◽  
Slow Release Formulation

Somatostatin analogs have been shown to be effective for the treatment of TSH-secreting pituitary adenomas. However, their use in this indication is limited by the fact that available analogs require several daily sc injections. The present study was performed to evaluate the effects of a slow release formulation of the somatostatin analog lanreotide (SR-L) on both hormone secretion and tumor size and to assess the tolerance in a series of thyrotropinomas treated for 6 months. Eighteen patients with hyperthyroidism related to a TSH-secreting pituitary adenoma, evidenced by pituitary magnetic resonance imaging, were studied. After a basal assessment, each patient received 30 mg SR-L, im, every 14 days for 1 month. Then, according to the free T3 (fT3) plasma level measured, 9 of 18 patients were injected twice monthly, and 7 of 18 patients received SR-L every 10 days for 5 additional months. One patient was dismissed from the study in month 1 of the study for side-effects and another in month 3 for noncompliance to the protocol. Clinical and biological evaluations (plasma TSH, free α-subunit, fT4, fT3, and lanreotide levels) were performed before and in months 1, 3, and 6 of treatment. Pituitary magnetic resonance imaging and gallbladder ultrasonography were performed both at entry and at the end of the study. Clinical signs of hyperthyroidism improved within 1 month in all 16 evaluable patients. Mean (±sem) plasma lanreotide levels reached 1.11 ± 0.43 and 1.69 ± 0.65 ng/mL in month 3 using 2 and 3 injections/month, respectively, then remained stable until the end of the study. During therapy, the plasma TSH level decreased from 2.72 ± 0.32 to 1.89 ± 0.27 mU/L (P &lt; 0.01), with parallel significant changes in free α-subunit. During the same period, plasma fT4 and fT3 levels decreased from 37.9 ± 2.9 to 19.7 ± 2.3 pmol/L (P &lt; 0.01) and from 14.6 ± 1.1 to 8.3 ± 0.8 pmol/L (P &lt; 0.01), respectively. No statistically significant change in mean adenoma size was observed after 6 months of treatment. Side-effects, including pain at the injection point, abdominal cramps, and diarrhea, were mild and transient and did not lead to interruption of the treatment. No gallstones occurred during the study. SR-L appears to be able to suppress clinical signs of hyperthyroidism in our series of patients with TSH-secreting pituitary adenomas. The analog also reduces plasma TSH and thyroid hormone levels, which were normalized in 13 of 16 cases. The effect was maintained throughout the treatment using 2 or 3 SR-L injections monthly without any problem of tolerance. We conclude that SR-L is a safe and effective treatment of thyrotropinomas and avoids the drawbacks of the modes of administration of other somatostatin analogs, given three times daily.

Sign in / Sign up

Export Citation Format

Share Document